How Long Do Allergy Shots Take to Work? It Depends What You're Measuring

The Combined Symptom and Medication Score (CSMS) is the primary efficacy endpoint recommended by EAACI for allergy immunotherapy trials because it captures both symptom burden and rescue medication use in a single composite measure. EAACI guidelines (Pfaar et al., Allergy 2014) defined meaningful CSMS improvement as 20-35% versus placebo. In well-designed trials, CSMS typically shows statistically significant improvement within the first treatment-overlapping allergy season — usually 6-12 months into maintenance dosing. The CSMS is particularly useful because patients often reduce medication use before noticing subjective symptom improvement, which can make them think 'nothing is happening' when objectively their medication burden is already declining. Tracking your antihistamine pill count alongside your symptom diary gives you a CSMS-equivalent personal measure.

Allergen-specific IgG4 blocking antibodies begin rising measurably within 8-12 weeks of starting allergy shots — earlier than any symptom change you would be able to notice. Shamji and Durham (JACI 2017) report that IgG4 continues rising for 1-3 years throughout the maintenance phase, ultimately reaching 10- to 100-fold higher levels than baseline in responding patients. Nikolov et al. (Antibodies 2021) documented a 14-fold rise in grass-specific IgG4 over 3 years of SCIT. These antibodies function by competitively binding allergen before IgE on mast cells can do so, blocking the allergic cascade at its source. However, IgG4 levels alone do not reliably predict clinical response — functional IgE-blocking activity (IgE-FAB assay) correlates better with symptoms than absolute antibody concentration (Shamji et al., Allergy 2012).

Quality-of-life improvements measured by validated questionnaires like the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) tend to lag behind symptom score improvements by 3-6 months, typically becoming meaningful around 12-18 months into maintenance. This lag occurs because quality-of-life assessments capture broader aspects of daily functioning — sleep quality, activity limitations, emotional impact, work productivity — that take longer to normalize than narrowly defined symptom scores. Juniper et al. (JACI 2004) established that the minimal important difference for RQLQ improvement is 0.5 points. Between-group improvements for immunotherapy versus placebo typically reach clinical meaningfulness within 12-18 months of consistent treatment, with gains continuing through year three for most patients.

Yes — and actively tracking your own progress significantly improves adherence and realistic expectation management. Useful self-tracking metrics include: (1) a daily symptom diary using a 0-3 scale for nasal congestion, sneezing, itchy eyes, and runny nose; (2) a medication diary tracking how many antihistamine or nasal spray doses you take per week; (3) seasonal comparison notes — how did this spring compare to last spring before treatment? (4) sleep quality tracking, since nasal congestion during sleep is often one of the first improvements patients notice. Makatsori et al. (Clin Transl Allergy 2014) found that patients who actively track their symptoms and maintain treatment self-efficacy beliefs have better adherence and better perceived outcomes than passive patients.

Prevention of new allergen sensitizations is one of the most compelling 'working' metrics for allergy shots — but it only becomes visible over years of follow-up, not months. Des Roches et al. (J Allergy Clin Immunol 1997) found that SCIT-treated dust-mite-monosensitized children were dramatically less likely to develop new sensitivities compared to untreated controls over a 3-year follow-up. Jacobsen et al. (Allergy 2007) documented similar protection at 10-year follow-up. This effect appears related to the regulatory immune environment established by SCIT — the same Treg and Breg populations that reduce existing allergy responses also suppress the development of new IgE-mediated sensitivities. For children especially, this prevention benefit may be more significant long-term than any single-season symptom score improvement.

Children and adults both benefit from allergy shots, but the evidence base differs in important ways. EAACI meta-analyses (Dhami et al., Allergy 2017) found adult effect sizes for SCIT were notably larger than pediatric effect sizes for symptom score reduction (SMD -0.56 adults vs. -0.25 children), though both were statistically significant. However, children may derive an additional benefit unavailable to adults: prevention of asthma development. The PAT study (Jacobsen et al., Allergy 2007) demonstrated that grass and birch SCIT in rhinitis-only children cut asthma development risk by roughly half at 10-year follow-up. Adults do not benefit from asthma prevention in the same way, though adult-onset asthma progression may be slowed. The minimum treatment age per most guidelines is five years, based on practical cooperation considerations rather than safety data.